Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 192 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acute Hospitalization Clear all
Terminated Phase 2Phase 3 Interventional Results available

NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients

NCT06000748
View directory record Official record
Conditions
Acute Kidney Injury, Cirrhosis, Portal Hypertension, Hepatorenal Syndrome, Acute Tubule Necrosis, Prerenal Failure
Interventions
MAP-Target Algorithm
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 1, 2026, 1:17 AM EDT
Terminated Not applicable Interventional

Impact of Negative Pressure Ventilation in Patients Hospitalized With Acute Hypercapnic Respiratory Failure

NCT06108284
View directory record Official record
Conditions
Acute Hypercapnic Respiratory Failure
Interventions
Intervention Arm (Biphasic cuirass ventilation)
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 1, 2026, 1:17 AM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

NCT04351152
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions
Lenzilumab, Standard of Care
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Nov 1, 2026, 1:17 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID

NCT06597396
View directory record Official record
Conditions
Post-COVID Condition, Fatigue Symptom
Interventions
Abrocitinib, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Nov 1, 2026, 1:17 AM EDT
Completed Phase 3 Interventional

Trial of Safety Nets In Hospitalized Patients

NCT00409370
View directory record Official record
Conditions
Delirium, Agitated Behavior, Alcohol Withdrawl, Acute Confusional State, Acute Psychosis
Interventions
SOMA safe enclosure
Device
Lead sponsor
Griffin Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Derby, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 8, 2006 · Synced Nov 1, 2026, 1:17 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia

NCT04369469
View directory record Official record
Conditions
COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
Interventions
Ravulizumab, BSC
Biological · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Nov 1, 2026, 1:17 AM EDT
Terminated Phase 2 Interventional Results available

Estradiol and Progesterone in Hospitalized COVID-19 Patients

NCT04865029
View directory record Official record
Conditions
Covid19
Interventions
Placebo injection and placebo pill, Estradiol Cypionate 5 mg/ml, Progesterone 200 mg Oral Capsule
Other · Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Nov 1, 2026, 1:17 AM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure

NCT02151383
View directory record Official record
Conditions
Acute Heart Failure
Interventions
Serelaxin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Up to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Denver, Colorado • St Louis, Missouri • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Nov 1, 2026, 1:17 AM EDT
Completed Phase 2 Interventional Results available

COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection

NCT04666441
View directory record Official record
Conditions
COVID-19
Interventions
REGN10933+REGN10987 combination therapy, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
57
States / cities
Mesa, Arizona • Tucson, Arizona • Canoga Park, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Nov 1, 2026, 1:17 AM EDT
Active, not recruiting No phase listed Observational

COVID-19 Outcome Prediction Algorithm

NCT05471011
View directory record Official record
Conditions
COVID-19, Post Acute Sequelae of COVID-19, Long COVID, Organ Dysfunction Syndrome, Multiple, Frailty Syndrome
Interventions
Blood and nasal swab sampling
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Sylmar, California • Torrance, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Nov 1, 2026, 1:17 AM EDT
Completed Phase 2 Interventional Results available

Thiamine and Acute Decompensated Heart Failure: Pilot Study

NCT00680706
View directory record Official record
Conditions
Heart Failure, Diabetes
Interventions
Thiamine, Placebo
Drug
Lead sponsor
Baystate Medical Center
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Nov 1, 2026, 1:17 AM EDT
Completed Phase 3 Interventional Results available

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

NCT01599806
View directory record Official record
Conditions
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Detroit, Michigan • St Louis, Missouri • Indiana, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Nov 1, 2026, 1:17 AM EDT
Completed Phase 3 Interventional Results available

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780437
View directory record Official record
Conditions
COVID-19
Interventions
AZD7442, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
1,455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
88
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Nov 1, 2026, 1:17 AM EDT
Completed No phase listed Observational Results available

Evaluation of the Mobile Acute Care of the Elderly (MACE) Unit

NCT00927160
View directory record Official record
Conditions
Model of Care for Hospitalized Older Adults
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
75 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Nov 1, 2026, 1:17 AM EDT
Recruiting Not applicable Interventional

DRAIN: DRainage in Acute Decompensated Heart faIlure With Pleural effusioNs

NCT07419360
View directory record Official record
Conditions
Congestive Heart Failure(CHF), Pleural Effusion Due to Congestive Heart Failure
Interventions
Thoracentesis
Procedure
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Nov 1, 2026, 1:17 AM EDT
Terminated Phase 3 Interventional

Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients

NCT04672564
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Carrimycin, Placebo
Drug
Lead sponsor
Shenyang Tonglian Group CO., Ltd
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Nov 1, 2026, 1:17 AM EDT
Recruiting Phase 2 Interventional

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

NCT06343792
View directory record Official record
Conditions
Steroid Refractory GVHD
Interventions
RLS-0071
Drug
Lead sponsor
ReAlta Life Sciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Duarte, California • Los Angeles, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Nov 1, 2026, 1:17 AM EDT
Terminated Phase 4 Interventional Results available

Azithromycin for Children Hospitalized With Asthma

NCT02003911
View directory record Official record
Conditions
Asthma
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
4 Years to 12 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Nov 1, 2026, 1:17 AM EDT
Recruiting Phase 2 Interventional

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab

NCT06701682
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions
Cohort A: vilobelimab, Cohort A: placebo
Drug
Lead sponsor
PPD Development, LP
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 1, 2026, 1:17 AM EDT
Completed Phase 3 Interventional Results available

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

NCT03345979
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole Lauroxil, Paliperidone Palmitate
Combination Product · Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Cerritos, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Nov 1, 2026, 1:17 AM EDT
Withdrawn No phase listed Observational

T2 Heart Mapping in AMI Population for the Prediction of Short Term Major Adverse Cardiovascular Events

NCT01796743
View directory record Official record
Conditions
Myocardial Infarction, Acute
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Nov 1, 2026, 1:17 AM EDT
Enrolling by invitation Not applicable Interventional

Impact of Exercise Groups on Patient Mental Health and Wellbeing in an Acute Psychiatric Inpatient Unit

NCT05859204
View directory record Official record
Conditions
Psychiatric Hospitalization, Physical Inactivity, Depression, Anxiety, Sleep
Interventions
OT-led Exercise Group, Treatment as Usual - OT Groups
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Nov 1, 2026, 1:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Maternal Mental Health in the Hospital Setting

NCT03777046
View directory record Official record
Conditions
Post Partum Depression
Interventions
Standard of Care (SOC), SOC with Psychology Therapy (CBT)
Behavioral
Lead sponsor
Michelle Lopez
Other
Eligibility
18 Years and older · Female only
Enrollment
545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Nov 1, 2026, 1:17 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

NCT05081388
View directory record Official record
Conditions
SARS-CoV-2
Interventions
REGN14256, imdevimab, casirivimab + imdevimab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
28
States / cities
La Mesa, California • Long Beach, California • Mission Viejo, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Nov 1, 2026, 1:17 AM EDT